Revance Therapeutics
RVNC
$3.32
Share price
-22.61%
Change (1 day)
-90.56%
Change (1 year)
Categories
P/S ratio for Revance Therapeutics (RVNC)
P/S ratio as of May 2024 (TTM): 1.48
According to Revance Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.47837. At the end of 2023 the company had a P/S ratio of 3.30.
P/S ratio history for Revance Therapeutics from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 3.30 | -71.21% |
| 2022 | 11.5 | -23.93% |
| 2021 | 15.1 | -87.76% |
| 2020 | 123 | -94.02% |
| 2019 | > 1000 | 930.89% |
| 2018 | 200 | -95.98% |
| 2017 | > 1000 | 152.17% |
| 2016 | > 1000 | -38.92% |
| 2015 | > 1000 | 206.32% |
| 2014 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.02 | 172.19% | 🇺🇸 USA |
 Biogen BIIB | 3.34 | 125.75% | 🇺🇸 USA |
 MediciNova MNOV | 75.0 | 4,975.91% | 🇺🇸 USA |